New Genetic Insights and Therapy in Multiple Myeloma
Year: 2007
Type: dissertation
Abstract: In the last decade, several significant advances in myeloma therapy have occurred with \nthe pace of change accelerated with the introduction of new anti-myeloma agents. The \napproach to the treatment of multiple myeloma has become more complex with an array \nof therapeutic options, including autologous stem cell transplantation, non-myeloablative \nallogeneic transplantation, and new therapeutic agents such as thalidomide, bortezomib, \nand lenalidomide. \n\nHigh-dose chemotherapy followed by autologous stem-cell transplantation has emerged \nas the most effective approach to achieve high complete response rates and thereby \nimprove the long-term overall survival. The majority of the patients, however, will develop \nprogressive disease within several years. For patients who are not suitable candidates for \nhigh-dose chemotherapy due to advanced age or poor performance status conventional \nchemotherapy has remained the most common treatment with a median overall survival \nof 3 years. Treatment options for patients with relapsed or refractory disease are limited. \nThe major obstacle to successful treatment of these patients is the development of drugresistant disease. \n\nThe analysis of genetic rearrangements in monoclonal gammopathy of undetermined \nsignificance (MGUS) and multiple myeloma by the use of cytogenetics and molecular \ncytogenetics has contributed significantly to our understanding of the development of \nclonal plasma cell disorders. Modern techniques such as fluorescence in situ hybridization \n(FISH) and comparative genomic hybridization (CGH) have revealed chromosomal \nabnormalities in virtually all patients with multiple myeloma and most patients with \nMGUS.
Author: Ka Lung Wu
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: multiple myeloma, monoclonal gammopathy of undetermined significance, chromosomal abnormalities, genome rearrangement, autologous stem cell transplantation, high-dose chemotherapy, thalidomide, bortezomib, lenalidomide, relapsed/refractory disease, drug resistance, clonal plasma cell disorder, cytogenetics, fluorescence in situ hybridization, comparative genomic hybridization
Open Access status: green
OpenAlex ID: W1591231876
